397 related articles for article (PubMed ID: 27211268)
1. KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.
Etchin J; Berezovskaya A; Conway AS; Galinsky IA; Stone RM; Baloglu E; Senapedis W; Landesman Y; Kauffman M; Shacham S; Wang JC; Look AT
Leukemia; 2017 Jan; 31(1):143-150. PubMed ID: 27211268
[TBL] [Abstract][Full Text] [Related]
2. Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice.
Etchin J; Montero J; Berezovskaya A; Le BT; Kentsis A; Christie AL; Conway AS; Chen WC; Reed C; Mansour MR; Ng CE; Adamia S; Rodig SJ; Galinsky IA; Stone RM; Klebanov B; Landesman Y; Kauffman M; Shacham S; Kung AL; Wang JC; Letai A; Look AT
Leukemia; 2016 Jan; 30(1):190-9. PubMed ID: 26202935
[TBL] [Abstract][Full Text] [Related]
3. The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.
Vercruysse T; De Bie J; Neggers JE; Jacquemyn M; Vanstreels E; Schmid-Burgk JL; Hornung V; Baloglu E; Landesman Y; Senapedis W; Shacham S; Dagklis A; Cools J; Daelemans D
Clin Cancer Res; 2017 May; 23(10):2528-2541. PubMed ID: 27780859
[No Abstract] [Full Text] [Related]
4. XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.
Ranganathan P; Kashyap T; Yu X; Meng X; Lai TH; McNeil B; Bhatnagar B; Shacham S; Kauffman M; Dorrance AM; Blum W; Sampath D; Landesman Y; Garzon R
Clin Cancer Res; 2016 Dec; 22(24):6142-6152. PubMed ID: 27358488
[TBL] [Abstract][Full Text] [Related]
5. Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies.
Hing ZA; Fung HY; Ranganathan P; Mitchell S; El-Gamal D; Woyach JA; Williams K; Goettl VM; Smith J; Yu X; Meng X; Sun Q; Cagatay T; Lehman AM; Lucas DM; Baloglu E; Shacham S; Kauffman MG; Byrd JC; Chook YM; Garzon R; Lapalombella R
Leukemia; 2016 Dec; 30(12):2364-2372. PubMed ID: 27323910
[TBL] [Abstract][Full Text] [Related]
6. Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.
Ranganathan P; Yu X; Santhanam R; Hofstetter J; Walker A; Walsh K; Bhatnagar B; Klisovic R; Vasu S; Phelps MA; Devine S; Shacham S; Kauffman M; Marcucci G; Blum W; Garzon R
Blood; 2015 Apr; 125(17):2689-92. PubMed ID: 25716206
[TBL] [Abstract][Full Text] [Related]
7. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
[TBL] [Abstract][Full Text] [Related]
9. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.
Zheng Y; Gery S; Sun H; Shacham S; Kauffman M; Koeffler HP
Cancer Chemother Pharmacol; 2014 Sep; 74(3):487-95. PubMed ID: 25030088
[TBL] [Abstract][Full Text] [Related]
10. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
[TBL] [Abstract][Full Text] [Related]
11. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.
Etchin J; Sanda T; Mansour MR; Kentsis A; Montero J; Le BT; Christie AL; McCauley D; Rodig SJ; Kauffman M; Shacham S; Stone R; Letai A; Kung AL; Thomas Look A
Br J Haematol; 2013 Apr; 161(1):117-27. PubMed ID: 23373539
[TBL] [Abstract][Full Text] [Related]
12. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
Gandhi UH; Senapedis W; Baloglu E; Unger TJ; Chari A; Vogl D; Cornell RF
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):335-345. PubMed ID: 29610030
[TBL] [Abstract][Full Text] [Related]
13. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.
Walker CJ; Oaks JJ; Santhanam R; Neviani P; Harb JG; Ferenchak G; Ellis JJ; Landesman Y; Eisfeld AK; Gabrail NY; Smith CL; Caligiuri MA; Hokland P; Roy DC; Reid A; Milojkovic D; Goldman JM; Apperley J; Garzon R; Marcucci G; Shacham S; Kauffman MG; Perrotti D
Blood; 2013 Oct; 122(17):3034-44. PubMed ID: 23970380
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
[TBL] [Abstract][Full Text] [Related]
15. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.
Ranganathan P; Yu X; Na C; Santhanam R; Shacham S; Kauffman M; Walker A; Klisovic R; Blum W; Caligiuri M; Croce CM; Marcucci G; Garzon R
Blood; 2012 Aug; 120(9):1765-73. PubMed ID: 22677130
[TBL] [Abstract][Full Text] [Related]
16. Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.
Crochiere M; Kashyap T; Kalid O; Shechter S; Klebanov B; Senapedis W; Saint-Martin JR; Landesman Y
BMC Cancer; 2015 Nov; 15():910. PubMed ID: 26573568
[TBL] [Abstract][Full Text] [Related]
17. XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).
Gravina GL; Tortoreto M; Mancini A; Addis A; Di Cesare E; Lenzi A; Landesman Y; McCauley D; Kauffman M; Shacham S; Zaffaroni N; Festuccia C
J Hematol Oncol; 2014 Oct; 7():46. PubMed ID: 25284315
[TBL] [Abstract][Full Text] [Related]
18. Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in
Zhang W; Ly C; Ishizawa J; Mu H; Ruvolo V; Shacham S; Daver N; Andreeff M
Haematologica; 2018 Oct; 103(10):1642-1653. PubMed ID: 29773601
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.
Attiyeh EF; Maris JM; Lock R; Reynolds CP; Kang MH; Carol H; Gorlick R; Kolb EA; Keir ST; Wu J; Landesman Y; Shacham S; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2016 Feb; 63(2):276-86. PubMed ID: 26398108
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor.
Subhash VV; Yeo MS; Wang L; Tan SH; Wong FY; Thuya WL; Tan WL; Peethala PC; Soe MY; Tan DSP; Padmanabhan N; Baloglu E; Shacham S; Tan P; Koeffler HP; Yong WP
Sci Rep; 2018 Aug; 8(1):12248. PubMed ID: 30115935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
